Medtronic plc held its 2024 Annual General Meeting on October 17, 2024, where shareholders voted on six key proposals. All ten nominated directors were elected to the Board, each to serve until the 2025 Annual General Meeting. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025.In addition, shareholders approved the non-binding advisory vote on named executive officer compensation, renewed the Board's authority to issue shares and opt out of pre-emption rights, and authorized the company to make overseas market purchases of Medtronic ordinary shares. The meeting had a quorum with 1,118,364,589 ordinary shares represented, out of 1,282,467,348 outstanding shares entitled to vote.Notably, all proposals received majority support, with the election of directors receiving between 90.6% and 99.5% approval. The non-binding vote on executive compensation passed with 92.4% support, while the renewal of share issuance authority and pre-emption rights opt-out received 97.9% and 93.2% approval, respectively.

Medtronic plc held its 2024 Annual General Meeting on October 17, 2024, where shareholders voted on six key proposals. All ten nominated directors were elected to the Board, each to serve until the 2025 Annual General Meeting. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025.In addition, shareholders approved the non-binding advisory vote on named executive officer compensation, renewed the Board's authority to issue shares and opt out of pre-emption rights, and authorized the company to make overseas market purchases of Medtronic ordinary shares. The meeting had a quorum with 1,118,364,589 ordinary shares represented, out of 1,282,467,348 outstanding shares entitled to vote.Notably, all proposals received majority support, with the election of directors receiving between 90.6% and 99.5% approval. The non-binding vote on executive compensation passed with 92.4% support, while the renewal of share issuance authority and pre-emption rights opt-out received 97.9% and 93.2% approval, respectively.